Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Nab-Paclitaxel in Relapsed NSCLC Adenocarcinoma
NCT03361319Phase 2Withdrawn
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial of nintedanib in lung adenocarcinoma (4 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Maximum Tolerated Dose at 2 years. Planned start Jul 2020; status: withdrawn.
02
Drugs
nintedanib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03361319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361319.